Evidence map›Paper›PMID 39944794›Full record

ArticleEJHaem2025

Hodgkin Lymphoma Treatment With Brentuximab Vedotin in a Patient With HIV, Liver Failure, and Anemia Without Transfusion.

Ellen Marin, Aseala Abousaud, Kathleen Davis, Bradley Sumrall, Shiyong Li, Amelia A Langston, Andres Chang

Abstract read
In one paragraph

Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ellen MarinDepartment of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta Georgia USA.
Aseala AbousaudDepartment of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta Georgia USA.
Kathleen DavisDepartment of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta Georgia USA.
Bradley SumrallCentral Georgia Cancer Care Macon Georgia USA.
Shiyong LiDepartment of Pathology Emory University School of Medicine Atlanta Georgia USA.
Amelia A LangstonDepartment of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta Georgia USA.
Andres ChangDepartment of Hematology and Medical Oncology Winship Cancer Institute Emory University School of Medicine Atlanta Georgia USA.ORCID https://orcid.org/0000-0001-6679-9060

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Emory Clinical Oncology Career Development Award K12 ProgramK12CA237806 · NCI · EMORY UNIVERSITY · PI DHODAPKAR, KAVITA MADHAV, RAMALINGAM, SURESH S · 2019 to 2023
$2.2M
Translational Physician-Scientist Training Program in OncologyT32CA160040 · NCI · EMORY UNIVERSITY · PI SHIN, DONG M · 2013 to 2017
$1.2M
SARS-CoV-2 immune responses in patients with lymphomaK08AI178093 · NIAID · EMORY UNIVERSITY · PI Andres Chang · 2024 to 2026
$579k
NCATS NIH HHS UL1 TR002378NCI NIH HHS K12 CA237806NCI NIH HHS T32 CA160040NIAID NIH HHS K08 AI178093
6 · The paper itself

Abstract

Brentuximab vedotin (BV) is a drug that has improved outcomes in classical Hodgkin lymphoma (cHL). However, its safety and efficacy in patients living with HIV who present with severe liver failure and life-threating cytopenias is unclear. Here, we describe the case of a woman living with HIV diagnosed with cHL and how she recovered from a hemoglobin nadir of 24 g/L despite declining transfusion support and a bilirubin peak of 417.24 µmol/L, eventually achieving a complete response with a BV-based therapy. Studies are needed to determine the safety and efficacy of BV in patients excluded from the pivotal trials.

Indexed as

anemiabrentuximab vedotincase reportHIVHodgkin lymphomaJehovah's Witnessliver failure

Identifiers

PMID39944794
PMCPMC11815334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.